Recent 8-K filings for MGTX
Highest-materiality recent filing
MeiraGTx closes initial $200M Hologen collaboration; Hologen to own 70% of neuro JV
- Completed initial closing of strategic collaboration with Hologen on April 20, 2026; Hologen provided $200M upfront cash payment.
- Hologen to fund remaining portion of upfront via post-completion share purchases, ultimately owning 70% of HNAI and minority stake in MeiraGTx Manufacturing.
-
MeiraGTx Q1 net loss $46.3M; reacquires bota-vec from J&J; raises $100M
Net loss attributable to ordinary shareholders was $46.3M ($0.57 per share) for Q1 2026, vs $40.0M ($0.51) in Q1 2025.
-
MeiraGTx closes initial $200M Hologen collaboration; Hologen to own 70% of neuro JV
Completed initial closing of strategic collaboration with Hologen on April 20, 2026; Hologen provided $200M upfront cash payment.
-
MeiraGTx reports positive 3-year Phase 1 data for AAV-hAQP1 in radiation-induced xerostomia
62% of patients had ≥10-point XQ improvement at 36 months; average 17-point improvement maintained from 12 months.
-
MeiraGTx acquires bota-vec gene therapy from Janssen for XLRP treatment
MeiraGTx paid $25M upfront to Janssen for bota-vec, with a potential $50M milestone upon US approval and $250M sales threshold.
-
MeiraGTx prices $100M public offering of 11.1M shares at $9.00 each; net proceeds ~$93.3M
11,111,111 ordinary shares at $9.00/sh; net proceeds ~$93.3M after underwriting discounts and expenses.
-
MeiraGTx: FDA Breakthrough for xerostomia, FY2025 net loss $114.2M, $200M Hologen JV
FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 for radiation-induced xerostomia; RMAT also granted.
-
MeiraGTx repurchases 2.3M shares from Perceptive Master Fund for $18.2M at $7.91 per share
Bought 2,300,000 ordinary shares from Perceptive Life Sciences Master Fund at VWAP of $7.91, aggregate $18.2M.
-
MeiraGTx Q3 net loss $50.5M; enters ophthalmology collaboration with Lilly for $75M upfront
Collaboration with Lilly: upfront $75M, eligible for >$400M milestones and tiered royalties on ocular programs.
-
MeiraGTx licenses AAV-AIPL1 and gene therapy tools to Lilly for $75M upfront, up to $400M milestones
Upfront payment of $75M; eligible for over $400M in total milestones, including up to $135M near-term.
-
MeiraGTx Q2 net loss narrows to $38.8M; FDA alignment on RIX pivotal study, RMAT for Parkinson's
Net loss $38.8M ($0.48/sh) vs $48.6M ($0.76/sh) in Q2 2024; cash $32.2M at June 30, 2025.
-
MeiraGTx receives UK FDI clearances for Hologen deal; closing expected July 2025
UK foreign direct investment clearances obtained for proposed transactions with Hologen Limited.
-
MeiraGTx annual meeting elects director, ratifies auditor
Director Thomas E. Shenk elected with 40.3M votes for, 9.1M withheld, 9.9M broker non-votes.
-
MeiraGTx Q1 net loss $40.0M; announces $200M Hologen AI collaboration, RMAT for AAV-GAD
Q1 net loss $40.0M ($0.51/share) vs $20.4M ($0.32) YoY; revenue $1.9M; cash $66.5M.
-
FDA grants RMAT designation to MeiraGTx's AAV-GAD for Parkinson's disease
RMAT designation based on data from three clinical studies (Phase 1 n=12, Phase 2 n=45, dose-ranging n=14).
-
MeiraGTx enters 7yr7mo lease for 14,235 sq ft NYC lab; terminates prior sublease
New lease with ARE-East River Science Park for lab/office space at $111/sq ft/yr, 3% annual escalations.
-
MeiraGTx enters collaboration with Hologen AI: $200M upfront, $230M JV funding for AAV-GAD
Received $200M upfront cash from Hologen; forming JV Hologen Neuro AI Ltd.
-
MeiraGTx granted FDA RMAT designation for AAV2-hAQP1 in Grade 2/3 radiation-induced xerostomia
FDA's RMAT designation includes Fast Track, Breakthrough Therapy benefits and potential Priority Review and accelerated approval.
-
MeiraGTx secures MHRA pathway for AAV-AIPL1 approval without further studies; Q3 net loss $39.3M
AAV-AIPL1 MAA under exceptional circumstances agreed with MHRA; no further clinical studies required for UK approval.
-
AAV-GAD met primary safety endpoint; no SAEs related to treatment in 14-patient bridging study.
-
MeiraGTx closes public offering of 12.5M shares at $4.00, netting $48.3M
Public offering of 12,500,000 ordinary shares at $4.00/share completed August 13, 2024; net proceeds ~$48.3M.
-
MeiraGTx reports Q2 net loss of $48.6M and $50M offering led by Sanofi
Net loss $48.6M ($0.76/share) vs $29.6M ($0.53) in Q2 2023; service revenue $0.3M, no license revenue.
-
MeiraGTx 2024 AGM results: directors elected, say-on-pay approved, auditor ratified
Three Class III directors elected: Forbes (99.8% cast, 49.6M for), Harris (99.5%), Mendoza (99.7%).
-
MeiraGTx Q1 net loss narrows to $20.4M; receives $50M milestone from Janssen
Net loss attributable to shareholders $20.4M ($0.32 per share) vs $30.4M ($0.62) in Q1 2023.
-
MeiraGTx amends prior 8-K to disclose Dr. Debra Yu's committee appointments
Debra Yu, M.D., joined the Board on April 25, 2022; this amendment adds committee assignments.
-
MeiraGTx reports FY2023 net loss of $84M, down 35% YoY; Janssen deal yields $50M milestone
Net loss $84.0M ($1.49/share) vs $129.6M ($2.87) in 2022; license revenue $14.0M.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.75 · Most common event earnings